Boehringer's biosimilar proves similarity to Humira

Boehringer Ingelheim has strengthened its position in the race to take a chunk of the sales of the world’s best-selling drug.

The privately-held German pharma major has announced one-year data from VOLTAIRE-RA, a pivotal Phase III trial comparing Boehringer’s biosimilar Cyltezo and the reference product Humira (adalimumab).

This data showed that Cyltezo is equivalent, with no clinically meaningful differences in efficacy, safety and immunogenicity, to Humira, in people with moderately-to-severely active rheumatoid arthritis (RA), including those who switched from the original drug to the biosimilar, at week 24.